Department of Internal Medicine, Hospital Poprad, Poprad, Slovakia.
Department of Epidemiology, PJ Safarik University, Faculty of Medicine, Kosice, Slovakia.
Int J Public Health. 2020 Jun;65(5):683-691. doi: 10.1007/s00038-020-01391-6. Epub 2020 Jun 4.
To determine both the incidence and the prevalence of primary biliary cholangitis (PBC) in Eastern Slovakia and to describe its clinical course and the response to ursodeoxycholic acid (UDCA).
We recorded data of patients with PBC, who were followed up in gastroenterology and hepatology centers in Eastern Slovakia during the period from June 30, 1999, through June 30, 2019.
The annual incidence of PBC varied from 0.7 to 1.5 cases per 100,000 inhabitants between 2014 and 2018. PBC prevalence steadily increased from initial 10.2 cases per 100,000 inhabitants in 2014 to 14.9 cases per 100,000 inhabitants in June 2019. The mean age at the time of diagnosis was 56.3 ± 10.9 years. 95.7% of patients were females, and female/male gender ratio was 22.3:1. In June 2019, prevalence in the female population was 28 cases per 100,000 women. At the time of diagnosis, three-quarters of patients were symptomatic and 10% of patients had liver cirrhosis. The mean follow-up was 7.3 ± 5.2 years. Response to UDCA was observed in 72.1% of patients. Patients with higher baseline alkaline phosphatase (ALP) levels, liver cirrhosis at entry or at the end of follow-up and women younger than 45 years responded worse to UDCA. One-quarter of patients had liver cirrhosis at the end of follow-up. During follow-up, 1.6% of patients underwent liver transplantation and 5.5% of patients died. Five-year and 10-year liver-related mortalities were 2.7% and 4.3%, respectively.
PBC prevalence in Eastern Slovakia is increasing, and most of the patients respond to therapy with UDCA.
确定斯洛伐克东部原发性胆汁性胆管炎（PBC）的发病率和患病率，并描述其临床过程和对熊去氧胆酸（UDCA）的反应。
我们记录了 1999 年 6 月 30 日至 2019 年 6 月 30 日期间在斯洛伐克东部胃肠病学和肝脏病学中心接受随访的 PBC 患者的数据。
2014 年至 2018 年期间，PBC 的年发病率为每 10 万人中有 0.7 至 1.5 例。PBC 的患病率从 2014 年最初的每 10 万人中有 10.2 例稳步上升至 2019 年 6 月的每 10 万人中有 14.9 例。诊断时的平均年龄为 56.3±10.9 岁。95.7%的患者为女性，女性/男性性别比为 22.3:1。2019 年 6 月，女性人群中的患病率为每 10 万女性中有 28 例。诊断时，四分之三的患者有症状，10%的患者有肝硬化。平均随访时间为 7.3±5.2 年。72.1%的患者对 UDCA 有反应。基线碱性磷酸酶（ALP）水平较高、入组时或随访结束时存在肝硬化以及年龄小于 45 岁的患者对 UDCA 的反应较差。随访结束时，四分之一的患者患有肝硬化。在随访期间，有 1.6%的患者接受了肝移植，有 5.5%的患者死亡。5 年和 10 年的肝脏相关死亡率分别为 2.7%和 4.3%。
斯洛伐克东部的 PBC 患病率正在上升，大多数患者对 UDCA 治疗有反应。
